TIGIT Antibody - (Research Grade tiragolumab Biosimilar) - Low Endotoxin, Azide and BSA Free

Novus Biologicals | Catalog # NBP3-28185

Recombinant Monoclonal Antibody
Novus Biologicals

Key Product Details

Species Reactivity

Human

Applications

ELISA, Flow Cytometry, Functional

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Human IgG1 expressed in CHO

Format

Low Endotoxin, Azide and BSA Free
Loading...

Product Specifications

Immunogen

TIGIT

Reactivity Notes

Predicted species reactivity: Mouse, Cynomolgus

Clonality

Monoclonal

Host

Human

Isotype

IgG1

Description

The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.

Also known as 'tiragolumab'.

This product is shipped at ambient temperature. Upon receipt, store immediately at -20C or lower for 12 months in a lyophilized state. - 80C for 3 months after reconstitution. Avoid repeated freeze-thaw cycles.

Endotoxin Level

< 0.001EU/ug,determined by LAL method.

Scientific Data Images

TIGIT Antibody (tiragolumab)

ELISA: TIGIT Antibody (tiragolumab)[NBP3-28185] -

Immobilized human TIGIT His at 2 ug/mL can bind TIGIT Antibody (tiragolumab), EC50=0.01643 ug/mL.
TIGIT Antibody (tiragolumab)

Functional: TIGIT Antibody (tiragolumab)[NBP3-28185] -

TIGIT Antibody (tiragolumab)-induced TIGIT Luciferase activity was evaluated using hu-TIGIT-CD226-NFAT-Jurkat,Reporter Cell. The EC50 was approximately 4.978nM.
TIGIT Antibody (tiragolumab)

Flow Cytometry: TIGIT Antibody (tiragolumab)[NBP3-28185] -

Human TIGIT HEK293 cells were stained with TIGIT Antibody (tiragolumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC50=0.2053 ug/mL.

Applications

Application
Recommended Usage

ELISA

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry

Optimal dilutions of this antibody should be experimentally determined.

Functional

Optimal dilutions of this antibody should be experimentally determined.

Flow Cytometry Panel Builder

Bio-Techne Knows Flow Cytometry

Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.

Advanced Features

  • Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
  • Spillover Popups - Visualize the spectra of individual fluorochromes
  • Antigen Density Selector - Match fluorochrome brightness with antigen density
Build Your Panel Now

Formulation, Preparation, and Storage

Purification

Protein A purified

Reconstitution

Reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

Formulation

Lyophilized from 25mM histidine, 8% sucrose, 0.01% Tween80 (pH6.2)

Format

Low Endotoxin, Azide and BSA Free

Preservative

No Preservative

Concentration

LYOPH mg/ml

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at -20C in powder form. Store at -80C once reconstituted.

Calculators

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Background: TIGIT

TIGIT (T cell Immunoreceptor with Ig and ITIM domains), also called Vstm3 (V-set and transmembrane domain-containing 3), Vsig9 (V-set and Ig domain-containing 9) and WUCAM (Washington University cell adhesion molecule), is a 30-34 kDa type I transmembrane protein that is a member of the CD28 family within the Ig superfamily of proteins (1-3). Human TIGIT cDNA encodes 244 amino acids (aa) including a 21 aa signal sequence, a 120 aa extracellular region with a V-type Ig-like domain and two potential N-glycosylation sites, a 21 aa transmembrane sequence, an 82 aa cytoplasmic domain with an immunoreceptor tyrosine-based inhibitory motif (ITIM) and has a theoretical molecular weight of ~27 kDa (3). TIGIT is expressed as a homodimer receptor on NK cells and subsets of activated, memory and regulatory T (Treg) cells, and on follicular helper T cells within secondary lymphoid organs (4). TIGIT has three known homodimer ligands that belong to the nectin family that are expressed on antigen presenting cells (APCs) or tumor cells (5). CD155 is the primary ligand for TIGIT, but it is also capable of binding CD112 and CD113 (5). The CD155/TIGIT signaling axis is an emerging immune checkpoint that inhibits function of T cells and NK cells. Upon TIGIT ligation, CD155 signaling leads to increased secretion of interleukin 10 (IL-10) and decreased secretion of proinflammatory cytokine IL-12 (5). TIGIT is a promising target for cancer immunotherapy and is the center of many pre-clinical studies investigating checkpoint blockade utilizing monoclonal antibodies either as a monotherapy or combination therapy (5).

TIGIT is commonly used as a marker for T cell exhaustion and its expression correlates with disease progression. Furthermore, in viral infections including HIV and SIV, TIGIT serves as a target for immune restoration (6). In cancer detection, TIGIT is upregulated and coexpressed with programmed cell death protein 1 (PD-1) on the majority of circulating tumor antigen (TA)-specific CD8+ T cells (7). In addition to this, TIGIT can inhibit immune cells at multiple steps within the cancer immunity cycle. These include inhibiting NK cell effector function, suppressing dendritic cell costimulatory abilities, suppressing CD8+ T cell effector function by Tregs or polio virus receptor (PVR)-stimulated myeloid cells, and by directly inhibiting CD8+ T cells and preventing elimination of cancer cells (7).

References

1. Joller, N., & Kuchroo, V. K. (2017). Tim-3, Lag-3, and TIGIT. Current topics in microbiology and immunology, 410, 127-156. https://doi.org/10.1007/82_2017_62

2. Xu, Z., Jin, B. A novel interface consisting of homologous immunoglobulin superfamily members with multiple functions. Cell Mol Immunol 7, 11-19 (2010). https://doi.org/10.1038/cmi.2009.108

3. Uniprot(P86176

4. Khan, M., Arooj, S., & Wang, H. (2020). NK Cell-Based Immune Checkpoint Inhibition. Frontiers in immunology, 11, 167. https://doi.org/10.3389/fimmu.2020.00167

5. Harjunpaa, H., & Guillerey, C. (2020). TIGIT as an emerging immune checkpoint. Clinical and experimental immunology, 200(2), 108-119. https://doi.org/10.1111/cei.13407

6. Blake, S. J., Dougall, W. C., Miles, J. J., Teng, M. W., & Smyth, M. J. (2016). Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research, 22(21), 5183-5188. https://doi.org/10.1158/1078-0432.CCR-16-0933

7. Manieri, N. A., Chiang, E. Y., & Grogan, J. L. (2017). TIGIT: A Key Inhibitor of the Cancer Immunity Cycle. Trends in immunology, 38(1), 20-28. https://doi.org/10.1016/j.it.2016.10.002

Long Name

T Cell Immunoreceptor with Ig and ITIM Domains

Alternate Names

VSIG9, VSTM3, WUCAM

Gene Symbol

Tigit

UniProt

Additional TIGIT Products

Product Documents

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot or batch number in the search box below.

Product Specific Notices

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customer Reviews

There are currently no reviews for this product. Be the first to review TIGIT Antibody - (Research Grade tiragolumab Biosimilar) - Low Endotoxin, Azide and BSA Free and earn rewards!

Have you used TIGIT Antibody - (Research Grade tiragolumab Biosimilar) - Low Endotoxin, Azide and BSA Free?

Submit a review and receive an Amazon gift card!

$25/€18/£15/$25CAN/¥2500 Yen for a review with an image

$10/€7/£6/$10CAN/¥1110 Yen for a review without an image

Submit a review
Amazon Gift Card

Protocols

Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.

FAQs

No product specific FAQs exist for this product.

View all FAQs for Antibodies